-
1
-
-
65349153684
-
The generalized anxiety spectrum: Prevalence, onset, course and outcome
-
Angst J, Gamma A, Baldwin DS, Ajdacic-Gross V, Rö ssler W (2009). The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 259:37-45.
-
(2009)
Eur Arch Psychiatry Clin Neurosci
, vol.259
, pp. 37-45
-
-
Angst, J.1
Gamma, A.2
Baldwin, D.S.3
Ajdacic-Gross, V.4
Rössler, W.5
-
2
-
-
27544471383
-
Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study
-
Brawman-Mintzer O, Knapp RG, Nieterts PJ (2005). Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66:1321-1325. (Pubitemid 41546513)
-
(2005)
Journal of Clinical Psychiatry
, vol.66
, Issue.10
, pp. 1321-1325
-
-
Brawman-Mintzer, O.1
Knapp, R.G.2
Nietert, P.J.3
-
4
-
-
19644370282
-
Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: A 12-year prospective study
-
DOI 10.1176/appi.ajp.162.6.1179
-
Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. (2005). Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:1179-1187. (Pubitemid 40770702)
-
(2005)
American Journal of Psychiatry
, vol.162
, Issue.6
, pp. 1179-1187
-
-
Bruce, S.E.1
Yonkers, K.A.2
Otto, M.W.3
Eisen, J.L.4
Weisberg, R.B.5
Pagano, M.6
Shea, M.T.7
Keller, M.B.8
-
5
-
-
0030670430
-
Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data
-
DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0. CO;2-E
-
Cnaan A, Laird NM, Slasor P (1997). Using the general linear model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16: 2349-2380. (Pubitemid 27458250)
-
(1997)
Statistics in Medicine
, vol.16
, Issue.20
, pp. 2349-2380
-
-
Cnaan, A.1
Laird, N.M.2
Slasor, P.3
-
6
-
-
0035884250
-
Sample size recalculation using conditional power
-
DOI 10.1002/sim.734
-
Denne JS (2001). Sample size recalculation using conditional power. Stat Med 20:2645-2660. (Pubitemid 32834374)
-
(2001)
Statistics in Medicine
, vol.20
, Issue.17-18
, pp. 2645-2660
-
-
Denne, J.S.1
-
7
-
-
0024887538
-
Testing for random dropouts in repeated measurement data
-
Diggle PJ (1989). Testing for random dropouts in repeated measurement data. Biometrics 45:1255-1258. (Pubitemid 20085467)
-
(1989)
Biometrics
, vol.45
, Issue.4
, pp. 1255-1258
-
-
Diggle, P.J.1
-
8
-
-
37349050303
-
Long-term efficacy of pregabalin in generalized anxiety disorder
-
DOI 10.1097/YIC.0b013e3282f0f0d7, PII 0000485020080100000003
-
Feltner D, Wittchen H-U, Kavoussi R, Brock J, Baldinetti F, Pande AC (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:18-28. (Pubitemid 350294866)
-
(2008)
International Clinical Psychopharmacology
, vol.23
, Issue.1
, pp. 18-28
-
-
Feltner, D.1
Wittchen, H.-U.2
Kavoussi, R.3
Brock, J.4
Baldinetti, F.5
Pande, A.C.6
-
10
-
-
84859265693
-
-
U.S. Dept of Health, Education, and Welfare, Public Health Service National Institute of Mental Health Psychopharmacology Research Branch, Division of Extramural Programs;
-
Rockville, MD: U.S. Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Programs; pp. 276-338.
-
Alcohol, Drug Abuse, and Mental Health Administration
, pp. 276-338
-
-
Rockville, M.D.1
-
11
-
-
51549099524
-
The assessment of anxiety states by rating
-
Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
-
(1959)
Br J Med Psychol
, vol.32
, pp. 50-55
-
-
Hamilton, M.1
-
13
-
-
0002105479
-
Application of random-effects pattern-mixture models for missing data in longitudinal studies
-
Hedeker D, Gibbons RD (1997). Applications of random-effects pattern mixture models for missing data in longitudinal studies. Psychol Methods 2:64-78. (Pubitemid 127453671)
-
(1997)
Psychological Methods
, vol.2
, Issue.1
, pp. 64-78
-
-
Hedeker, D.1
Gibbons, R.D.2
-
14
-
-
35648988598
-
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
-
DOI 10.1177/0269881107076996
-
Hidalgo RB, Tupler LA, Davidson JR (2007). An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864-872. (Pubitemid 350029180)
-
(2007)
Journal of Psychopharmacology
, vol.21
, Issue.8
, pp. 864-872
-
-
Hidalgo, R.B.1
Tupler, L.A.2
Davidson, J.R.T.3
-
15
-
-
38949154090
-
Human and economic burden of generalized anxiety disorder
-
DOI 10.1002/da.20257
-
Hoffman DL, Dukes EM,Wittchen H-U (2008). Human and economic burden of generalized anxiety disorder. Depress Anxiety 25:72-90. (Pubitemid 351213928)
-
(2008)
Depression and Anxiety
, vol.25
, Issue.1
, pp. 72-90
-
-
Hoffman, D.L.1
Dukes, E.M.2
Wittchen, H.-U.3
-
16
-
-
46949106005
-
Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder
-
Hoge EA,Worthington JJ 3rd, Kaufman RE, Delong HR, Pollack MH, Simon NM (2008). Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spect 13:522-527. (Pubitemid 351960777)
-
(2008)
CNS Spectrums
, vol.13
, Issue.6
, pp. 522-527
-
-
Hoge, E.A.1
Worthington III, J.J.2
Kaufman, R.E.3
Delong, H.R.4
Pollack, M.H.5
Simon, N.M.6
-
17
-
-
53149142767
-
Quetiapine as an adjunctive pharmacotherapy for the treatment of nonremitting generalized anxiety disorder: A flexible-dose, open-label pilot trial
-
Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, et al. (2008). Quetiapine as an adjunctive pharmacotherapy for the treatment of nonremitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 22:1480-1486.
-
(2008)
J Anxiety Disord
, vol.22
, pp. 1480-1486
-
-
Katzman, M.A.1
Vermani, M.2
Jacobs, L.3
Marcus, M.4
Kong, B.5
Lessard, S.6
-
18
-
-
0032697699
-
Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys
-
Kessler RC, DuPont RL, Berglund P, Wittchen H-U (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923.
-
(1999)
Am J Psychiatry
, vol.156
, pp. 1915-1923
-
-
Kessler, R.C.1
Dupont, R.L.2
Berglund, P.3
Wittchen, H.-U.4
-
19
-
-
20344385026
-
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication
-
DOI 10.1001/archpsyc.62.6.593
-
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
-
(2005)
Archives of General Psychiatry
, vol.62
, Issue.6
, pp. 593-602
-
-
Kessler, R.C.1
Berglund, P.2
Demler, O.3
Jin, R.4
Merikangas, K.R.5
Walters, E.E.6
-
20
-
-
70449529019
-
Discrete sequential boundaries for clinical trials
-
Lan KKG, DeMets DL (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659-663.
-
(1983)
Biometrika
, vol.70
, pp. 659-663
-
-
Lan, K.K.G.1
Demets, D.L.2
-
21
-
-
0023677293
-
The B-value: A tool for monitoring data
-
Lan KKG, Wittes J (1988). The B-value: a tool for monitoring data. Biometrics 44:579-585.
-
(1988)
Biometrics
, vol.44
, pp. 579-585
-
-
Lan, K.K.G.1
Wittes, J.2
-
22
-
-
0037273401
-
Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations
-
DOI 10.1081/BIP-120019265
-
Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G (2003). Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 13:179-190. (Pubitemid 36523156)
-
(2003)
Journal of Biopharmaceutical Statistics
, vol.13
, Issue.2
, pp. 179-190
-
-
Mallinckrodt, C.H.1
Clark, W.S.2
Carroll, R.J.3
Molenberghs, G.4
-
23
-
-
0003541554
-
-
designed experiments. New York: Van Nostrand Reinhold
-
Milliken GA, Johnson DE (1986). Analysis of messy data, volume 1: designed experiments. New York: Van Nostrand Reinhold.
-
(1986)
Analysis of Messy Data
, vol.1
-
-
Milliken, G.A.1
De, J.2
-
24
-
-
15444365574
-
A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder
-
DOI 10.1097/01.jcp.0000155821.74832.f9
-
Mitte K, Noack P, Steil R, Hautzinger M (2005). A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25:141-150. (Pubitemid 40395092)
-
(2005)
Journal of Clinical Psychopharmacology
, vol.25
, Issue.2
, pp. 141-150
-
-
Mitte, K.1
Noack, P.2
Steil, R.3
Hautzinger, M.4
-
25
-
-
55949104118
-
Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder
-
Montgomery S, Chatamra K, Pauer L,Whalen E, Baldinetti F (2008). Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 193:389-394.
-
(2008)
Br J Psychiatry
, vol.193
, pp. 389-394
-
-
Montgomery, S.1
Chatamra, K.2
Pauer, L.3
Whalen, E.4
Baldinetti, F.5
-
26
-
-
33750125418
-
Pregabalin for the treatment of generalised anxiety disorder
-
Montgomery SA (2006). Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 7:2139-2154.
-
(2006)
Expert Opin Pharmacother
, vol.7
, pp. 2139-2154
-
-
Montgomery, S.A.1
-
27
-
-
80051549520
-
Pharmacotherapy update: Pregabalin in the treatment of generalized anxiety disorder
-
Montgomery SA, Kasper S (2010). Pharmacotherapy update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Ther 2:189-202.
-
(2010)
Clin Med Insights Ther
, vol.2
, pp. 189-202
-
-
Montgomery, S.A.1
Kasper, S.2
-
28
-
-
49149131149
-
Development and evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder
-
Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, et al. (2008). Development and evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J Psychiatr Res 42:1024-1036.
-
(2008)
J Psychiatr Res
, vol.42
, pp. 1024-1036
-
-
Morlock, R.J.1
Williams, V.S.2
Cappelleri, J.C.3
Harness, J.4
Fehnel, S.E.5
Endicott, J.6
-
29
-
-
0018687930
-
A multiple testing procedure for clinical trials
-
DOI 10.2307/2530245
-
O'Brien PC, Fleming TR (1979). A multiple testing procedure for clinical trials. Biometrics 35:549-556. (Pubitemid 10242750)
-
(1979)
Biometrics
, vol.35
, Issue.3
, pp. 549-556
-
-
O'Brien, P.C.1
Fleming, T.R.2
-
30
-
-
32144450616
-
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study
-
DOI 10.1016/j.biopsych.2005.07.005, PII S0006322305008528
-
Pollack MH, Simon NM, Zalta AK,Worthington JJ, Hoge EA, Mick E, et al. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211-215. (Pubitemid 43208966)
-
(2006)
Biological Psychiatry
, vol.59
, Issue.3
, pp. 211-215
-
-
Pollack, M.H.1
Simon, N.M.2
Zalta, A.K.3
Worthington, J.J.4
Hoge, E.A.5
Mick, E.6
Kinrys, G.7
Oppenheimer, J.8
-
31
-
-
0029589385
-
Designed extension of studies based on conditional power
-
DOI 10.2307/2533262
-
Proschan MA, Hunsberger SA (1995). Designed extension of studies based on conditional power. Biometrics 51:1315-1324. (Pubitemid 26030176)
-
(1995)
Biometrics
, vol.51
, Issue.4
, pp. 1315-1324
-
-
Proschan, M.A.1
Hunsberger, S.A.2
-
32
-
-
0026325551
-
Testing for random dropouts in repeated measurement data, reader reaction
-
Ridout MS (1991). Testing for random dropouts in repeated measurement data, reader reaction. Biometrics 47:1617-1621.
-
(1991)
Biometrics
, vol.47
, pp. 1617-1621
-
-
Ridout, M.S.1
-
33
-
-
5444232126
-
Primary care perspectives on generalized anxiety disorder
-
Roy-Byrne PP, Wagner A (2004). Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 65 (Suppl 13):20-26.
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.13 SUPPL.
, pp. 20-26
-
-
Roy-Byrne, P.P.1
Wagner, A.2
-
35
-
-
0030753736
-
The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability
-
DOI 10.1016/S0924-9338(97)83297-X
-
Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, et al. (1997). The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12:232-241. (Pubitemid 27298916)
-
(1997)
European Psychiatry
, vol.12
, Issue.5
, pp. 232-241
-
-
Sheehan, D.V.1
Lecrubier, Y.2
Sheehan, K.H.3
Janavs, J.4
Weiller, E.5
Keskiner, A.6
Schinka, J.7
Knapp, E.8
Sheehan, M.F.9
Dunbar, G.C.10
-
36
-
-
33645774689
-
An open-label trial of risperidone augmentation for refractory anxiety disorders
-
Simon NM, Hoge EA, Fischmann D,Worthington JJ, Christian KM, Kinrys G, et al. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381-385.
-
(2006)
J Clin Psychiatry
, vol.67
, pp. 381-385
-
-
Simon, N.M.1
Hoge, E.A.2
Fischmann, D.3
Worthington, J.J.4
Christian, K.M.5
Kinrys, G.6
-
37
-
-
41849148995
-
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: Preliminary findings
-
Simon NM, Connor KM, LeBeau RT, Hoge EA,Worthington JJ III, Zhang W, et al. (2008). Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology 197:675-681.
-
(2008)
Psychopharmacology
, vol.197
, pp. 675-681
-
-
Simon, N.M.1
Connor, K.M.2
Lebeau, R.T.3
Hoge, E.A.4
Worthington Iii, J.J.5
Zhang, W.6
-
38
-
-
25444460399
-
Open-label pilot study of ziprasidone for refractory generalized anxiety disorder [2]
-
DOI 10.1097/01.jcp.0000177853.15910.de
-
Snyderman SH, Rynn MA, Rickels K (2005). Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 25:497-499. (Pubitemid 41368377)
-
(2005)
Journal of Clinical Psychopharmacology
, vol.25
, Issue.5
, pp. 497-499
-
-
Snydermae, S.H.1
Rynn, M.A.2
Rickels, K.3
-
39
-
-
33847286912
-
2-delta) subunit as a target for antiepileptic drug discovery
-
DOI 10.1016/j.eplepsyres.2006.09.008, PII S0920121106003895
-
Taylor CP, Angelotti T, Fauman E (2007). Pharmacology and mechanism of action of pregabalin: the calcium channel a2-d (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73:137-150. (Pubitemid 46329329)
-
(2007)
Epilepsy Research
, vol.73
, Issue.2
, pp. 137-150
-
-
Taylor, C.P.1
Angelotti, T.2
Fauman, E.3
-
40
-
-
27744458830
-
Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia
-
DOI 10.1002/da.20089
-
Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB (2005). Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 22:59-67. (Pubitemid 41598041)
-
(2005)
Depression and Anxiety
, vol.22
, Issue.2
, pp. 59-67
-
-
Vasile, R.G.1
Bruce, S.E.2
Goisman, R.M.3
Pagano, M.4
Keller, M.B.5
-
41
-
-
0036093608
-
Generalized anxiety and depression in primary care: Prevalence, recognition, and management
-
Wittchen H-U, Kessler RC, Beesdo K, Krause P, Hö fler M, Hoyer J (2002). Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl 8):24-34. (Pubitemid 34535254)
-
(2002)
Journal of Clinical Psychiatry
, vol.63
, Issue.SUPPL. 8
, pp. 24-34
-
-
Wittchen, H.-U.1
Kessler, R.C.2
Beesdo, K.3
Krause, P.4
Hofler, M.5
Hoyer, J.6
-
43
-
-
0026878098
-
Benzodiazepines: Use, abuse, and consequences
-
Woods JH, Katz JL, Winger G (1992). Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151-347.
-
(1992)
Pharmacol Rev
, vol.44
, pp. 151-347
-
-
Woods, J.H.1
Katz, J.L.2
Winger, G.3
|